BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

670 related articles for article (PubMed ID: 27913862)

  • 1. Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma.
    Unger U; Denkert C; Braicu I; Sehouli J; Dietel M; Loibl S; Darb-Esfahani S
    Virchows Arch; 2017 Feb; 470(2):143-151. PubMed ID: 27913862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. APOBEC3B protein expression and mRNA analyses in patients with high-grade serous ovarian carcinoma.
    Rüder U; Denkert C; Kunze CA; Jank P; Lindner J; Jöhrens K; Kulbe H; Sehouli J; Dietel M; Braicu E; Darb-Esfahani S
    Histol Histopathol; 2019 Apr; 34(4):405-417. PubMed ID: 30289149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma.
    Liebscher CA; Prinzler J; Sinn BV; Budczies J; Denkert C; Noske A; Sehouli J; Braicu EI; Dietel M; Darb-Esfahani S
    Hum Pathol; 2013 Aug; 44(8):1465-71. PubMed ID: 23465277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anterior gradient protein 2 (AGR2) is an independent prognostic factor in ovarian high-grade serous carcinoma.
    Darb-Esfahani S; Fritzsche F; Kristiansen G; Weichert W; Sehouli J; Braicu I; Dietel M; Denkert C
    Virchows Arch; 2012 Aug; 461(2):109-16. PubMed ID: 22752467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High expression of NQO1 is associated with poor prognosis in serous ovarian carcinoma.
    Cui X; Li L; Yan G; Meng K; Lin Z; Nan Y; Jin G; Li C
    BMC Cancer; 2015 Apr; 15():244. PubMed ID: 25885439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HUR mRNA expression in ovarian high-grade serous carcinoma effusions is associated with poor survival.
    Davidson B; Holth A; Hellesylt E; Hadar R; Katz B; Tropé CG; Reich R
    Hum Pathol; 2016 Feb; 48():95-101. PubMed ID: 26640230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HSP60 predicts survival in advanced serous ovarian cancer.
    Hjerpe E; Egyhazi S; Carlson J; Stolt MF; Schedvins K; Johansson H; Shoshan M; Avall-Lundqvist E
    Int J Gynecol Cancer; 2013 Mar; 23(3):448-55. PubMed ID: 23429486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advanced high-grade serous ovarian cancer: inverse association of KLK13 and KLK14 mRNA levels in tumor tissue and patients' prognosis.
    Dettmar L; Ahmed N; Kotzsch M; Diersch S; Napieralski R; Darmoul D; Schmitt M; Weichert W; Kiechle M; Dorn J; Magdolen V
    J Cancer Res Clin Oncol; 2018 Jun; 144(6):1109-1118. PubMed ID: 29546479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of Ki-67 levels and hormone receptor expression in low-grade serous ovarian carcinoma: an investigation of the Tumor Bank Ovarian Cancer Network.
    Sehouli J; Braicu EI; Richter R; Denkert C; Jank P; Jurmeister PS; Kunze CA; Budczies J; Darb-Esfahani S; Schmitt WD; Traut A; Grabowski J; Taube ET; Plett H
    Hum Pathol; 2019 Mar; 85():299-308. PubMed ID: 30428389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of Notch 3 gene expression in ovarian serous carcinoma.
    Jung SG; Kwon YD; Song JA; Back MJ; Lee SY; Lee C; Hwang YY; An HJ
    Cancer Sci; 2010 Sep; 101(9):1977-83. PubMed ID: 20624166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pretreatment maximum standardized uptake value in 18F-fluorodeoxyglucose positron emission tomography-computed tomography as a prognostic factor for ovarian clear cell carcinoma and low-grade serous carcinoma.
    Matsuura T; Otsuka I; Ouchi T; Ouchi E; Asano R; Miyasaka N
    Taiwan J Obstet Gynecol; 2021 Mar; 60(2):305-310. PubMed ID: 33678332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.
    Darb-Esfahani S; Kunze CA; Kulbe H; Sehouli J; Wienert S; Lindner J; Budczies J; Bockmayr M; Dietel M; Denkert C; Braicu I; Jöhrens K
    Oncotarget; 2016 Jan; 7(2):1486-99. PubMed ID: 26625204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma.
    Gorovetz M; Baekelandt M; Berner A; Trope' CG; Davidson B; Reich R
    Gynecol Oncol; 2006 Dec; 103(3):831-40. PubMed ID: 16919315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TGFβ splicing and canonical pathway activation in high-grade serous carcinoma.
    Gutgold N; Davidson B; Catane LJ; Holth A; Hellesylt E; Tropé CG; Dørum A; Reich R
    Virchows Arch; 2017 Jun; 470(6):665-678. PubMed ID: 28432432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinicopathologic study and immunohistochemistry comparison of Pax2, p53 and Ki-67 in low- and high-grade ovarian serous carcinomas].
    Shen XX; Yu L; Bi R; Yang WT
    Zhonghua Bing Li Xue Za Zhi; 2011 Aug; 40(8):511-6. PubMed ID: 22169637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study.
    Koutras A; Kalogeras KT; Wirtz RM; Alexopoulou Z; Bobos M; Zagouri F; Veltrup E; Timotheadou E; Gogas H; Pentheroudakis G; Pisanidis N; Magkou C; Christodoulou C; Bafaloukos D; Papakostas P; Aravantinos G; Pectasides D; Kalofonos HP; Fountzilas G
    J Transl Med; 2015 May; 13():171. PubMed ID: 26021752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nicotinamide N-methyltransferase overexpression may be associated with poor prognosis in ovarian cancer.
    Harmankaya İ; Akar S; Uğraş S; Güler AH; Ezveci H; Aydoğdu M; Çelik Ç
    J Obstet Gynaecol; 2021 Feb; 41(2):248-253. PubMed ID: 32285726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low RAP80 mRNA expression correlates with shorter survival in sporadic high-grade serous ovarian carcinoma.
    Romeo M; Karachaliou N; Chaid I; Queralt C; De Aguirre I; Del Carmen Gómez M; Sanchez-Ronco M; Radua J; Ramírez JL; Rosell R
    Int J Biol Markers; 2017 Mar; 32(1):e90-e95. PubMed ID: 27443420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of TP53 and AGR3 to distinguish ovarian high-grade serous carcinoma from low-grade serous carcinoma.
    Qiu C; Wang Y; Wang X; Zhang Q; Li Y; Xu Y; Jin C; Bu H; Zheng W; Yang X; Lu N; Kong B
    Int J Oncol; 2018 Jun; 52(6):2041-2050. PubMed ID: 29620196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients.
    Gayarre J; Kamieniak MM; Cazorla-Jiménez A; Muñoz-Repeto I; Borrego S; García-Donas J; Hernando S; Robles-Díaz L; García-Bueno JM; Ramón Y Cajal T; Hernández-Agudo E; Heredia Soto V; Márquez-Rodas I; Echarri MJ; Lacambra-Calvet C; Sáez R; Cusidó M; Redondo A; Paz-Ares L; Hardisson D; Mendiola M; Palacios J; Benítez J; García MJ
    J Gynecol Oncol; 2016 Jan; 27(1):e7. PubMed ID: 26463438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.